医药魔方2023-07-26 10:06
7月24日,Syndax Pharmaceuticals和Incyte共同宣布,抗CSF-1R单抗axatilimab在既往接受过二线及以上治疗后疾病进展的慢性移植物抗宿主病(GVHD)成人和儿童患者中的II期AGAVE-201研究取得了积极的关键数据。
网页链接{点...查看全文
产业链观察2023-07-26 01:35
#药闻简讯# 7月24日,$Syndax制药(SNDX)$ 和$因塞特医疗(INCY)$ 共同宣布,抗CSF-1R单抗axatilimab在既往接受过二线及以上治疗后疾病进展的慢性移植物抗宿主病(GVHD)成人和儿童患者中的II期AGAVE-201研究取得了积极的关键数据。
AGAVE-201研究是一项随机、开放标签的II期临床试验,共纳入241...查看全文
SeekingBiotech2023-07-24 22:03
SNDX and Incyte announced topline data from the pivotal AGAVE-201 trial of axatilimab in adult and pediatric patients with chronic graft-versus-host disease (GVHD) following two or more prior lines of therapy. The trial achieved its primary endpoint across all cohorts
$S...查看全文
药融云医药大数据2023-05-16 16:11
据CDE官网最新公示,成都苑东生物4类化药磷酸芦可替尼片的仿制药上市申请获受理。2022年,该JAK抑制剂全球大卖了$40亿,国内销售额也同比增长23%,达到4亿。目前,该品种在国内尚无仿制药获批,国内首仿药虚位以待。
截图来源:CDE官网
芦可替尼是由Incyte开发的选择性JAK抑制剂(JAK1/JAK...查看全文
智通财经APP获悉,当地时间6月13日,美国FDA宣布批准礼来(LLY.US)和因塞特(INCY.US)联合开发的口服JAK抑制剂巴瑞替尼(英文商品名Olumiant)上市,用于治疗严重斑秃成人患者。值得一提的是,这是美国FDA批准用于治疗斑秃的首款系统性疗法... 网页链接
智通财经APP获悉,美国FDA于当地时间7月29日扩大了礼来(LLY.US)与因塞特医疗(INCY.US)的baricitinib药物(商用名Olumiant)的紧急适用授权(EUA)。根据修订后的EUA,治疗确诊新冠的住院患者时,baricitinib不需与吉利德科学(GILD.US)的Vekl... 网页链接
$因塞特(INCY)$ 8-K - Current report Filed: 2017-02-14 AccNo: 0001104659-17-008850 Size: 308 KBItem 2.02: Results of Operations and Financial ConditionItem 9.01: Financial Statements and Exhibits 网页链接
$因塞特(INCY)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2017-02-13 AccNo: 0000932471-17-002530 Size: 43 KB 网页链接
$因塞特(INCY)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2017-02-10 AccNo: 0000932471-17-002140 Size: 48 KB 网页链接
$因塞特(INCY)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2017-02-09 AccNo: 0000902219-17-000213 Size: 38 KB 网页链接
$因塞特(INCY)$ 美东时间 2017-02-14 盘前 披露财报,预期EPS 0.14 网页链接
$因塞特(INCY)$ SC 13G - Statement of acquisition of beneficial ownership by individuals Filed: 2017-01-31 AccNo: 0001104659-17-005380 Size: 60 KB 网页链接
$因塞特(INCY)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2017-01-25 AccNo: 0000353480-17-001034 Size: 13 KB 网页链接
$因塞特(INCY)$ 8-K - Current report Filed: 2017-01-23 AccNo: 0001104659-17-003535 Size: 21 KBItem 8.01: Other Events 网页链接
$因塞特(INCY)$ SC 13G - Statement of acquisition of beneficial ownership by individuals Filed: 2017-01-23 AccNo: 0001104659-17-003533 Size: 70 KB 网页链接
$因塞特(INCY)$ 内部交易: 2017-01-09,EVP, Chief Scientific Officer,Huber Reid M ,卖出,11739普通股, $113.55